Core Insights - Servier has announced the acquisition of Day One Biopharmaceuticals for $21.50 per share, totaling an equity value of approximately $2.5 billion, expected to close in Q2 2026 [2][3][5] Group 1: Acquisition Details - The acquisition price represents a premium of approximately 68% over Day One's closing price on March 5, 2026, and an 86% premium over the one-month volume weighted average price as of the same date [5] - Servier plans to fund the acquisition through existing cash and investments [6] - The transaction is subject to customary closing conditions, including majority shareholder tender and U.S. antitrust clearance [7] Group 2: Strategic Implications - This acquisition will enhance Servier's position in oncology targeted therapies, aligning with its 2030 ambition to develop innovative treatments for patients with high unmet medical needs [3][4] - The combination of Day One's expertise in pediatric low-grade glioma and Servier's global capabilities aims to accelerate innovation in rare cancers [4] - Servier's commitment to investing in science and advancing targeted therapies is emphasized as a key driver for this acquisition [4][11] Group 3: Company Background - Servier is an independent international pharmaceutical group with a focus on therapeutic progress and patient needs, distributing medicines in over 130 countries [10][12] - Day One Biopharmaceuticals is dedicated to developing targeted therapies for pediatric cancer, addressing critical unmet needs in this area [12][13]